| 4.435 0.535 (13.72%) | 10-21 13:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.83 | 1-year : | 6.82 |
| Resists | First : | 4.99 | Second : | 5.84 |
| Pivot price | 4.46  |
|||
| Supports | First : | 3.64 | Second : | 3.02 |
| MAs | MA(5) : | 3.93 |
MA(20) : | 4.67 |
| MA(100) : | 5.44 |
MA(250) : | 7.77 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 18.4 |
D(3) : | 9.7 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 16.6 | Low : | 3.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AARD ] has closed above bottom band by 46.9%. Bollinger Bands are 7.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.01 - 4.04 | 4.04 - 4.06 |
| Low: | 3.72 - 3.75 | 3.75 - 3.78 |
| Close: | 3.85 - 3.9 | 3.9 - 3.95 |
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Tue, 20 Oct 2026
Attention Long-Term Shareholders of Aardvark Therapeutics, - GlobeNewswire
Sat, 10 Oct 2026
URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges - GlobeNewswire
Thu, 08 Oct 2026
AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire
Thu, 08 Oct 2026
Attention Long-Term Shareholders of Aardvark Therapeutics, - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 52.5 (%) |
| Shares Short | 474 (K) |
| Shares Short P.Month | 510 (K) |
| EPS | -3.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.4 % |
| Return on Equity (ttm) | -66.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | 0 |
| Price to Book value | 1.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|